<p> New Delhi: Zydus Lifesciences on Tuesday said it has launched a medication for testosterone suppression in patients with advanced prostate cancer.</p>.<p> The company has launched the oral once-a-day therapy under the brand name Rexigo.</p>.<p> The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options.</p>.<p> 'With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life,' Zydus Lifesciences said in a regulatory filing.</p>.<p> Prostate cancer is one of the leading cancers in men and more than 43,000 cases were reported in India in 2022 as per the National Cancer Registry Program of India.</p>
<p> New Delhi: Zydus Lifesciences on Tuesday said it has launched a medication for testosterone suppression in patients with advanced prostate cancer.</p>.<p> The company has launched the oral once-a-day therapy under the brand name Rexigo.</p>.<p> The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options.</p>.<p> 'With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life,' Zydus Lifesciences said in a regulatory filing.</p>.<p> Prostate cancer is one of the leading cancers in men and more than 43,000 cases were reported in India in 2022 as per the National Cancer Registry Program of India.</p>